NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What is the indication for using a PDE-4 inhibitor like Rolumilast (Daliresp) in COPD treatment?

Initial treatment of mild COPD
Very severe COPD, chronic bronchitis, and history of exacerbations
Acute exacerbation of COPD
As monotherapy in mild to moderate COPD

The correct answer is: Very severe COPD, chronic bronchitis, and history of exacerbations

PDE-4 inhibitors like Roflumilast (Daliresp) are indicated for use in very severe COPD, particularly in patients with chronic bronchitis and a history of exacerbations. This class of medication is not typically recommended as initial treatment for mild COPD, as in option A. Additionally, PDE-4 inhibitors are not used in the acute exacerbation setting, as in option C, but rather for long-term maintenance therapy in specific severe COPD cases. Lastly, using a PDE-4 inhibitor as monotherapy in mild to moderate COPD, as suggested in option D, is not a typical practice due to their specific indication for severe cases with chronic bronchitis and a history of exacerbations.